[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"gastric-cancer-diagnosis\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:gastric-cancer-diagnosis":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,15,0,[8,43,72,99,128,157,181,208,231,254,291,314,338,368,387],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":28,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":31,"lastUpdatePostDateStruct":32,"startDateStruct":35,"completionDateStruct":37,"leadSponsor":39,"locationsCount":42},"100644061","phase-2-a-study-on-the-efficacy-and-safety-of-sintilimab-combined-with-ramucirumab-and-paclitaxel-in-the-treatment-of-gastric-cancer-patients-with-short-term-recurrence-after-adjuvant-therapy-100644061",false,"NCT07669740","A Study on the Efficacy and Safety of Sintilimab Combined With Ramucirumab and Paclitaxel in the Treatment of Gastric Cancer Patients With Short-term Recurrence After Adjuvant Therapy","A Study on the Efficacy and Safety of Sintilimab Combined With Ramucirumab and Paclitaxel in the Treatment of Gastric Cancer Patients With Short-Term Recurrence After Adjuvant Therapy","Inclusion Criteria:\n\n* Age ≥18 years at the time of informed consent.\n* Histologically confirmed gastric or gastroesophageal junction (GEJ)adenocarcinoma.\n* HER2-negative disease, as determined by standard testing methods.\n* Prior D2 radical gastrectomy with R0 resection.\n* Disease recurrence during adjuvant chemotherapy or within 6 months after completion of adjuvant chemotherapy.\n* At least one measurable lesion according to RECIST version 1.1.\n* Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2.\n* Adequate organ and bone marrow function.\n* Life expectancy of at least 3 months.\n* Ability to understand and willingness to sign written informed consent.\n\nExclusion Criteria:\n\n* Active malignancy within the past 5 years, except for adequately treated in situ carcinoma or other cancers with a negligible risk of recurrence.\n* Prior participation in another investigational drug study within 4 weeks prior to enrollment.\n* Symptomatic central nervous system (CNS) metastases.\n* Active autoimmune disease requiring systemic treatment.\n* Uncontrolled cardiovascular disease or uncontrolled hypertension.\n* History of thromboembolic events or clinically significant bleeding disorders within 6 months prior to enrollment.\n* Active tuberculosis or interstitial lung disease.\n* Known hypersensitivity to monoclonal antibodies or any excipients of the study drug.","ALL","15 Years","75 Years",{"count":20,"type":21},30,"ESTIMATED","INTERVENTIONAL",[24],"PHASE2","To explore the efficacy and safety of sintilimab combined with ramucirumab and paclitaxel in the treatment of advanced gastric cancer patients with short-term recurrence after postoperative adjuvant therapy, and to identify efficacy-related biomarkers to guide subsequent individualized treatment.",[27],"Gastric Cancer (Diagnosis)",[29],"gastric cancer","NOT_YET_RECRUITING","2026-06-22",{"date":33,"type":34},"2026-06-25","ACTUAL",{"date":36,"type":21},"2026-07-01",{"date":38,"type":21},"2028-12-30",{"name":40,"class":41},"The First Affiliated Hospital with Nanjing Medical University","OTHER",1,{"id":44,"slug":45,"hasResults":11,"nctId":46,"briefTitle":47,"officialTitle":48,"acronym":49,"eligibilityCriteria":50,"healthyVolunteers":11,"sex":16,"minAge":51,"maxAge":4,"enrollmentInfo":52,"targetDuration":4,"studyType":22,"phases":54,"briefSummary":55,"conditions":56,"keywords":58,"overallStatus":62,"whyStopped":4,"lastUpdateSubmitDate":63,"lastUpdatePostDateStruct":64,"startDateStruct":66,"completionDateStruct":68,"leadSponsor":70,"locationsCount":42},"100641848","phase-2-taic-folfox-for-locally-advanced-ggeja-100641848","NCT07655024","TAIC FOLFOX for Locally Advanced G\u002FGEJA","FOLFOX-Based Transarterial Infusion Chemotherapy for Locally Advanced Gastric Cancer and Gastroesophageal Junction Adenocarcinoma: Protocol of an Open-Label, Multicentre, Single-arm, Phase Ⅱ Trial","TFLAG","Inclusion Criteria:\n\n* Age ≥ 18 years\n* Pathologically diagnosed with G\u002FGEJA\n* Confirmed by the surgeon as initially unresectable advanced G\u002FGEJC\n* Contraindicated to surgery due to frailty or comorbidities\n* Expected survival period ≥ 3 months\n\nExclusion Criteria:\n\n* Primary malignant tumors\n* Gastrointestinal obstruction caused by lesions in the distal stomach, duodenum, pancreas or other organs\n* Acute infection, severe liver or kidney dysfunction or coagulation disorder\n* Allergic to the drugs or with mental disorders","18 Years",{"count":53,"type":21},31,[24],"Gastric cancer is the fifth most common malignancy worldwide in terms of both incidence and mortality. The majority of cases are diagnosed at advanced stage-often presenting with severe complications such as malignant stricture, obstruction, bleeding, and cancer-related malnutrition-which impinge on quality of life and survival outcomes. For patients with unresectable or metastatic gastric cancer and gastroesophageal junction adenocarcinoma (G\u002FGEJA), first-line systemic therapy remains predominantly platinum- and fluoropyrimidine-based combination chemotherapy, and targeted agents or immunotherapy can be added based on the expression of biomarkers. Under this standard approach, the median overall survival (mOS) for localized unresectable G\u002FGEJA is approximately 14-20 months. For metastatic G\u002FGEJA, the prognosis remains poor with an mOS of less than 1 year, despite the proven efficacy of chemotherapeutic agents. Moreover, up to 25% of cancer survivors report a significant decline in quality of life due to gastrointestinal symptoms during, soon after, or many years after treatment.\n\nInterventional oncology approaches-including trans-arterial infusion chemotherapy (TAIC), embolization (TAE), and chemoembolization (TACE)-represent promising locoregional therapeutic strategies. TAIC allows for the direct delivery of cytotoxic agents into the tumor-feeding arteries, thereby maximizing intra-tumoral drug concentration. As one of the most well-recognized applications, hepatic arterial infusion chemotherapy (HAIC) has been demonstrated in liver cancer by elevating local drug exposure, markedly enhancing antitumor efficacy while minimizing systemic adverse effects. Moreover, chemotherapeutic agents may exert secondary systemic activity against clinically or subclinically disseminated metastases upon systemic circulation, contributing to a sustained \"secondary chemotherapy\" effect. Owing to its favorable safety profile and preserved antitumor activity, TAIC is particularly suited for frail or elderly patients who are ineligible for surgery or conventional systemic chemotherapy.\n\nGiven the persistent limitations of current therapeutic paradigms, the feasibility and safety of trans-arterial therapy in the treatment of anti-tumor, hemostasis and obstruction relief for locally advanced G\u002FGEJC remains urgent. The present study aimed to assess the efficacy and safety of TAIC for locally advanced G\u002FGEJA.",[27,57],"Gastroesophageal Junction Adenocarcinoma",[59,60,61],"Unresectable Gastric cancer","Esophagogastric junction adenocarcinoma","Transarterial infusion chemotherapy","RECRUITING","2026-06-15",{"date":65,"type":34},"2026-06-17",{"date":67,"type":34},"2025-11-01",{"date":69,"type":21},"2028-12-01",{"name":71,"class":41},"Guang'anmen Hospital of China Academy of Chinese Medical Sciences",{"id":73,"slug":74,"hasResults":11,"nctId":75,"briefTitle":76,"officialTitle":77,"acronym":78,"eligibilityCriteria":79,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":80,"targetDuration":4,"studyType":22,"phases":82,"briefSummary":84,"conditions":85,"keywords":86,"overallStatus":62,"whyStopped":4,"lastUpdateSubmitDate":90,"lastUpdatePostDateStruct":91,"startDateStruct":93,"completionDateStruct":95,"leadSponsor":97,"locationsCount":42},"100642236","two-component-radiology-guided-autonomous-cascade-engine-trace-100642236","NCT07651644","Two-component Radiology-guided Autonomous Cascade Engine (TRACE)","Protocol for a Prospective Randomised Crossover Controlled Trial of the Artificial Intelligence-Assisted Decision-Making System for Gastric Cancer T-Staging (TRACE)","TRACE","Inclusion Criteria (Imaging Data)\n\n1. Contrast-enhanced CT (CE-CT) images of gastric cancer patients from the Liaoning Cancer Hospital;\n2. Patients with a definitive postoperative pathological diagnosis of gastric cancer and a clear T-stage classification (T1-T4, including T4a and T4b);\n3. Imaging data must be complete and of sufficient quality to meet diagnostic and analytical requirements, with no significant artefacts or missing key data;\n4. Complete clinical and pathological information must be available to establish a diagnostic gold standard for comparison.\n\nPhysician Inclusion Criteria (Image Readers)\n\n1. Radiologists holding a valid medical licence;\n2. From the radiology department of a Grade A tertiary hospital or a non-Grade A tertiary hospital;\n3. Classified as senior or junior physicians based on clinical experience;\n4. Voluntarily participating in this study and completing both the non-AI-assisted and AI-assisted image interpretation tasks.\n\nCase Exclusion Criteria\n\n1. Severe missing imaging data or quality failing to meet analysis requirements (e.g., severe motion artefacts);\n2. Lack of clear postoperative pathological T-staging results;\n3. Cases not involving gastric cancer or with incomplete pathological information;\n4. Cases of duplicate enrolment or inconsistent data recording.\n\nPhysician Exclusion Criteria\n\n1. Those unable to complete all image review tasks or demonstrating severe non-compliance;\n2. Those who withdraw during the study period and are unable to provide complete data for both phases of image review;\n3. Those who fail to complete the AI-assisted and non-AI-assisted interpretation processes as specified.\n\nWithdrawal Criteria\n\n1. Physicians who voluntarily withdraw from the study for personal reasons (e.g., time, health or work commitments);\n2. Physicians who fail to complete the required image review tasks or have data missing in excess of the specified threshold;\n3. Cases where critical data errors are identified during subsequent verification or where pathological results cannot be traced; Data found during the study to be non-compliant with ethical or quality control requirements must be excluded.",{"count":81,"type":21},54,[83],"NA","This study employed a prospective, randomised crossover trial design to evaluate the clinical utility of the TRACE artificial intelligence system for gastric cancer T-staging. A total of 54 radiologists from tertiary and non-tertiary hospitals, including both senior and junior practitioners, were enrolled. The study aimed to investigate whether AI-assisted diagnosis could improve the diagnostic accuracy of gastric cancer T-staging compared with independent interpretation by radiologists.\n\nAll participants were required to interpret 60 contrast-enhanced CT cases sequentially, completing two readings for each case: one without AI assistance and one with AI assistance; The order of the two readings was randomised, and a one-month washout period was observed between readings to eliminate memory bias. All cases were pathologically confirmed gastric cancer cases (stages T1-T4b), and the study simultaneously recorded the physicians' T-staging diagnostic results and the time taken per case. The 60 cases per radiologist were randomly selected from a pool of 1,000 histologically confirmed gastric cancer cases, stratified by pathological T stage T1-T4b. The reference standard was postoperative pathological T stage. The primary outcome was the change in T-staging accuracy between AI-assisted reading and standard (unaided) reading.The term \"prospective\" in this study refers to the prospective execution of radiologist enrollment, randomization, reading procedures, and data collection.",[27],[87,88,89],"AI","Gastric Cancer","T Stage","2026-06-11",{"date":92,"type":34},"2026-06-16",{"date":94,"type":21},"2026-06-18",{"date":96,"type":21},"2026-08-07",{"name":98,"class":41},"Liaoning Cancer Hospital & Institute",{"id":100,"slug":101,"hasResults":11,"nctId":102,"briefTitle":103,"officialTitle":104,"acronym":105,"eligibilityCriteria":106,"healthyVolunteers":11,"sex":16,"minAge":51,"maxAge":4,"enrollmentInfo":107,"targetDuration":4,"studyType":22,"phases":109,"briefSummary":110,"conditions":111,"keywords":113,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":120,"lastUpdatePostDateStruct":121,"startDateStruct":122,"completionDateStruct":123,"leadSponsor":125,"locationsCount":127},"100642922","recovery-after-cancer-application-100642922","NCT07642492","REcovery After Cancer Application","REcovery After Cancer Application (RECapp) - Personalised Support After Surgery for Oesophageal and Gastric Cancer Patients","RECapp","Inclusion Criteria\n\n* Patients who have undergone invasive surgery with curative intent for oesophageal or gastric cancer (including salvage surgery)\n* ≥18 years of age\n* Ability to read, understand, and complete study materials in Swedish, including consent forms, questionnaires, and instructions\n* Access to a smartphone or tablet with personal BankID\n\nExclusion Criteria\n\n\\- Cognitive impairment",{"count":108,"type":21},250,[83],"The RECapp study is a clinical trial evaluating a digital tool designed to support patients recovering from surgery for oesophageal or stomach cancer. The goal is to reduce symptoms and improve quality of life during recovery.\n\nEach year in Sweden, around 1,400 people are diagnosed with these cancers. Although more people are surviving thanks to better treatments, recovery after surgery is often long and challenging, with lasting physical and emotional effects. At the same time, healthcare systems are under pressure to provide long-term support.\n\nRECapp is a digital platform developed together with patients and healthcare professionals. It includes a mobile app for patients and a web portal for healthcare staff. Patients can track their symptoms, receive personalised self-care advice, and get guidance on when to contact healthcare. Healthcare providers can follow patients' progress remotely.\n\nIn this study, 250 patients from across Sweden will take part. They will be randomly assigned to either standard care or standard care plus RECapp. Participants will be followed for six months after surgery, and their symptoms and quality of life will be regularly assessed through questionnaires.\n\nIf RECapp proves effective, it could become part of future cancer care in Sweden-helping patients feel better supported while also making care more efficient.",[112,27],"Oesophageal Cancer",[114,115,116,117,118,119],"Oesophageal cancer","Gastric cancer","Post surgery","Digital intervention","Symptom monitoring","Self-care advice","2026-06-07",{"date":90,"type":34},{"date":63,"type":21},{"date":124,"type":21},"2029-12-15",{"name":126,"class":41},"Karolinska Institutet",7,{"id":129,"slug":130,"hasResults":11,"nctId":131,"briefTitle":132,"officialTitle":133,"acronym":4,"eligibilityCriteria":134,"healthyVolunteers":11,"sex":16,"minAge":51,"maxAge":4,"enrollmentInfo":135,"targetDuration":4,"studyType":22,"phases":137,"briefSummary":138,"conditions":139,"keywords":142,"overallStatus":62,"whyStopped":4,"lastUpdateSubmitDate":148,"lastUpdatePostDateStruct":149,"startDateStruct":151,"completionDateStruct":152,"leadSponsor":154,"locationsCount":156},"100636142","exercise-training-after-upper-gastrointestinal-cancer-surgery-100636142","NCT07561840","Exercise Training After Upper Gastrointestinal Cancer Surgery","Exercise and Cardiorespiratory Fitness Improvement Through Supervised Training in Upper Gastrointestinal Cancer Surgery Patients (EXCITING-UGI)","Inclusion Criteria:\n\n* Age ≥ 18 years\n* Diagnosed with esophageal or gastric cancer\n* Received curative surgery\n* 6 ± 2 weeks after surgery\n* Ability to provide written informed consent\n\nExclusion Criteria:\n\n* Communication difficulties\n* Poor general status\n* Undergone combined laryngopharyngectomy\n* Unsuitable for evaluation or exercise intervention\n* Unsuitable for the study as determined by the primary physician",{"count":136,"type":21},171,[83],"This randomized controlled trial aims to determine the optimal exercise intensity for improving postoperative recovery in patients with upper gastrointestinal cancer. Participants who have undergone curative surgery will be randomly assigned to high-intensity interval training (HIIT), low-intensity continuous training (LICT), or usual care. The exercise interventions will be performed under supervision three times per week for eight weeks. The primary outcome is peak oxygen uptake (VO₂peak), assessed using cardiopulmonary exercise testing. Secondary outcomes include physical function, body composition, patient-reported outcomes, and biological and mechanistic markers such as inflammatory biomarkers, muscle-related factors, and gut microbiota. This study will also explore potential mechanisms underlying exercise-induced adaptations and their association with clinical outcomes.",[140,27,141],"Esophageal Cancer","Upper Gastrointestinal Cancer",[143,144,145,146,147],"upper gastrointestinal cancers","exercise","high-intensity interval training","randomized controlled trial","exercise oncology","2026-05-15",{"date":150,"type":34},"2026-05-19",{"date":148,"type":34},{"date":153,"type":21},"2029-11",{"name":155,"class":41},"Kansai Medical University",2,{"id":158,"slug":159,"hasResults":11,"nctId":160,"briefTitle":161,"officialTitle":161,"acronym":162,"eligibilityCriteria":163,"healthyVolunteers":11,"sex":16,"minAge":51,"maxAge":4,"enrollmentInfo":164,"targetDuration":4,"studyType":22,"phases":166,"briefSummary":167,"conditions":168,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":174,"lastUpdatePostDateStruct":175,"startDateStruct":176,"completionDateStruct":177,"leadSponsor":179,"locationsCount":4},"100638325","statewide-unified-network-for-remote-intervention-of-strength-and-exercise-100638325","NCT07596732","Statewide Unified Network for Remote Intervention of Strength and Exercise","SUNRISE","Inclusion Criteria:\n\n* Gastrointestinal cancer (esophageal, gastric, pancreatic, colon, and rectal) treated with chemotherapy (and other treatments, as clinically indicated) before surgery OR Lung cancer (non-small cell and small-cell) treated with chemotherapy (and other treatments, as clinically indicated) for advanced- or extensive-stage disease.\n* Completion of the modified version of the Physical Activity Readiness Questionnaire.\n\nExclusion Criteria:\n\n* Actively treated for another non-gastrointestinal or non-lung malignancy (surveillance with observation is allowed).\n* Engage in more than 150 minutes per week of aerobic physical activity and two or more sessions of muscle strengthening activity per week over the last three months (self-report).\n* Unable to walk for 6 minutes or two city blocks independently (self-report).\n* Enrollment in another study that intervenes upon physical activity, diet, or body composition as a primary objective (self-report).\n* Unable to read and speak English.\n* No access to a reliable internet connection.\n* Currently an AdventHealth employee.",{"count":165,"type":21},120,[83],"This study will evaluate whether a remotely delivered exercise program can improve chemotherapy tolerability in patients with gastrointestinal or lung cancer receiving chemotherapy.\n\nIn this decentralized, digital randomized clinical trial, up to 120 adults with gastrointestinal or lung cancer will be randomized to either a home-based aerobic and resistance exercise program or home-based progressive stretching program. All study activities will be conducted remotely using digital technologies and home-based assessments. Participants in both groups will receive Bluetooth-enabled wearable devices for monitoring physical activity, body weight, blood pressure, and other health measures.\n\nThe primary objective is to determine whether exercise improves chemotherapy relative dose intensity compared with stretching. The intervention will continue throughout chemotherapy treatment or for up to 32 weeks.",[27,169,170,171,172,173],"Esophagus Cancer","Pancreas Cancer","Colon Cancer","Rectal Cancer","Lung Cancer","2026-05-13",{"date":150,"type":34},{"date":36,"type":21},{"date":178,"type":21},"2027-12-31",{"name":180,"class":41},"AdventHealth Translational Research Institute",{"id":182,"slug":183,"hasResults":11,"nctId":184,"briefTitle":185,"officialTitle":186,"acronym":4,"eligibilityCriteria":187,"healthyVolunteers":11,"sex":16,"minAge":51,"maxAge":4,"enrollmentInfo":188,"targetDuration":4,"studyType":22,"phases":190,"briefSummary":191,"conditions":192,"keywords":195,"overallStatus":62,"whyStopped":4,"lastUpdateSubmitDate":198,"lastUpdatePostDateStruct":199,"startDateStruct":201,"completionDateStruct":203,"leadSponsor":205,"locationsCount":207},"100616588","high-flow-nasal-cannula-for-preventing-hypoxia-during-sedated-endoscopy-in-high-risk-obstructive-sleep-apnea-patients-100616588","NCT07307560","High-Flow Nasal Cannula for Preventing Hypoxia During Sedated Endoscopy in High-Risk Obstructive Sleep Apnea Patients","High-Flow Nasal Cannula for Preventing Hypoxia During Sedated Endoscopy in High-Risk Obstructive Sleep Apnea Patients: A Multicenter Randomized Trial","Inclusion Criteria:\n\n* Age ≥18 years.\n* STOP-Bang score ≥5.\n* Scheduled for sedated gastrointestinal endoscopy (gastroscopy, colonoscopy, or combined gastroscopy + colonoscopy).\n* The estimated duration of the procedure does not exceed 45 minutes.\n* Patients have signed the informed consent form.\n\nExclusion Criteria:\n\n* Coagulation disorders or bleeding tendency (e.g., oral\u002Fnasal bleeding risk, mucosal injury, space-occupying obstructions).\n* Active upper respiratory tract infection (oral, nasal, or pharyngeal), or fever (core temperature \\>37.5°C).\n* Chronic obstructive pulmonary disease or other acute\u002Fchronic pulmonary diseases requiring long-term or intermittent oxygen therapy, or preoperative SpO₂ ≤ 92% on room air.\n* Severe organ dysfunction, including: Cardiac insufficiency (\\\u003C4 METs), Severe renal insufficiency (requiring dialysis), Diagnosed severe hepatic insufficiency, Increased intracranial pressure, ASA physical status ≥ IV.\n* Confirmed pregnancy or current breastfeeding.\n* Known allergy to sedatives (e.g., propofol) or medical adhesives.\n* Multiple traumatic injuries.\n* Current participation in another clinical trial.\n* Other conditions deemed unsuitable by the investigator",{"count":189,"type":21},600,[83],"Hypoxia represents the most frequent adverse event during propofol-sedated gastrointestinal endoscopy. The STOP-BANG questionnaire serves as a widely adopted, straightforward tool for screening obstructive sleep apnea (OSA) risk, with a score ≥5 identifying high-risk OSA patients who are particularly susceptible to hypoxia under sedation. Although preliminary research from our team suggests that High-Flow Nasal Cannula (HFNC) may lower the incidence of hypoxemia, evidence remains limited and inconsistent in studies specifically targeting high-risk OSA populations. Therefore, this multicenter randomized controlled trial aims to evaluate whether HFNC can effectively reduce the occurrence of hypoxia during sedated gastrointestinal endoscopy in patients identified as high-risk for OSA.",[193,140,27,194],"Hypoxia","Obstructive Sleep Apnea (OSA)",[196,193,194,197],"Sedation","Gastrointestinal Endoscopy","2026-05-01",{"date":200,"type":34},"2026-05-04",{"date":202,"type":34},"2025-12-21",{"date":204,"type":21},"2026-12-01",{"name":206,"class":41},"Zhejiang University",3,{"id":209,"slug":210,"hasResults":11,"nctId":211,"briefTitle":212,"officialTitle":213,"acronym":4,"eligibilityCriteria":214,"healthyVolunteers":11,"sex":16,"minAge":51,"maxAge":215,"enrollmentInfo":216,"targetDuration":218,"studyType":219,"phases":4,"briefSummary":220,"conditions":221,"keywords":4,"overallStatus":62,"whyStopped":4,"lastUpdateSubmitDate":223,"lastUpdatePostDateStruct":224,"startDateStruct":226,"completionDateStruct":228,"leadSponsor":229,"locationsCount":42},"100623787","deepcomp-for-prediction-of-gastric-cancer-postoperative-complications-deepcomp-prospective-100623787","NCT07401173","DeepComp for Prediction of Gastric Cancer Postoperative Complications (DeepComp-Prospective)","A Prospective, Multicenter, Observational Study Validating the Multimodal Deep Learning Radiomics Model (DeepComp) for Preoperative Prediction of Major Postoperative Complications in Patients With Gastric Cancer","Inclusion Criteria:\n\nAge ≥ 18 years.\n\nHistologically confirmed gastric adenocarcinoma.\n\nScheduled for elective radical gastrectomy (open, laparoscopic, or robotic) with curative intent.\n\nStandard preoperative contrast-enhanced abdominal CT scans (venous phase) performed within 14 days prior to surgery.\n\nWillingness to sign informed consent.\n\nExclusion Criteria:\n\nEmergency surgery due to perforation, obstruction, or massive bleeding.\n\nIntraoperative findings of distant metastasis (Stage IV) or unresectable disease preventing R0 resection.\n\nConcurrent or previous malignant tumors within the last 5 years (except gastric cancer).\n\nPregnancy or lactation.\n\nSevere metallic artifacts on CT images preventing radiomic analysis.","85 Years",{"count":217,"type":21},500,"30 Days","OBSERVATIONAL","Gastric cancer is a leading cause of cancer-related mortality, and radical surgery remains the primary treatment. However, postoperative complications are common and can significantly impact patient recovery and quality of life. Currently, doctors lack precise tools to accurately predict which patients are at high risk for developing severe complications before surgery.\n\nThis study aims to validate a novel artificial intelligence (AI) model called \"DeepComp.\" The DeepComp model integrates clinical data with advanced radiomic features derived from routine preoperative CT scans. Specifically, it analyzes both the tumor characteristics and the patient's body composition (including skeletal muscle and fat distribution) to assess physiological reserve.\n\nIn this prospective, multicenter observational study, researchers will enroll patients scheduled for gastric cancer surgery across five medical centers. The DeepComp model will be used to predict the risk of moderate-to-severe postoperative complications (Clavien-Dindo grade II or higher). These predictions will then be compared with the actual clinical outcomes observed 30 days after surgery. The goal is to determine the accuracy and reliability of the DeepComp model in a real-world clinical setting, potentially providing a powerful tool for personalized surgical risk assessment.",[27,222],"Postoperative Complications","2026-04-06",{"date":225,"type":34},"2026-04-09",{"date":227,"type":34},"2026-03-01",{"date":198,"type":21},{"name":230,"class":41},"Qun Zhao",{"id":232,"slug":233,"hasResults":11,"nctId":234,"briefTitle":235,"officialTitle":236,"acronym":4,"eligibilityCriteria":237,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":238,"targetDuration":240,"studyType":219,"phases":4,"briefSummary":241,"conditions":242,"keywords":244,"overallStatus":62,"whyStopped":4,"lastUpdateSubmitDate":245,"lastUpdatePostDateStruct":246,"startDateStruct":248,"completionDateStruct":250,"leadSponsor":252,"locationsCount":42},"100632726","the-ugira-international-registry-for-ramig-for-gastric-cancer-100632726","NCT07517432","The UGIRA International Registry for RAMIG for Gastric Cancer","The UGIRA International Registry for Robot-Assisted Minimally Invasive Gastrectomy (RAMIG) for Gastric Cancer","Inclusion Criteria:\n\n* All gastric cancer patients undergoing RAMIG in a center\n\nExclusion Criteria:\n\n* No",{"count":239,"type":21},200,"10 Years","Minimally invasive gastrectomy (MIG) has gained in popularity, since it is feasible, safe and oncologically comparable to open gastrectomy, while morbidity and duration of hospitalization are reduced, quality of life is increased, and conversion rate is low.\n\nHowever, several challenges are faced during MIG, such as impaired depth perception and limited range of motion of instrument tips. Robot-Assisted Minimally Invasive Gastrectomy (RAMIG) can potentially overcome these challenges, while providing comparable results regarding safety, technical feasibility, morbidity and oncological effectiveness. However, the techniques and outcomes of RAMIG vary in literature, which can partly be explained by lack of uniform definitions of postoperative outcomes that would allow international comparison. Furthermore, RAMIG is technically demanding and therefore associated with a learning curve.\n\nTo facilitate safe and effective implementation of RAMIG worldwide, the learning curve for RAMIG-procedures must be evaluated in detail. A prospective international registry with uniform data collection regarding surgical techniques and postoperative outcomes can provide a platform for multicontinental studies and the monitoring of surgical quality for surgeons who are implementing RAMIG in their center. Therefore, the aim of this study proposal is to expand the Upper Gastrointestinal International Robotic Association (UGIRA) collaboration by creating the UGIRA International Registry for RAMIG. The UGIRA network extends worldwide with members in Europe, Asia, North-America and South-America, therefore representing large-scale practice of RAMIG. The initial specific aims of the registry are to gain insight in surgical techniques and postoperative outcomes of RAMIG worldwide, and to evaluate the learning curve for RAMIG.\n\nData for this registry is collected prospectively and retrospectively.",[27,243],"Gastrectomy",[29,243],"2026-04-01",{"date":247,"type":34},"2026-04-08",{"date":249,"type":34},"2021-04-01",{"date":251,"type":21},"2031-03-31",{"name":253,"class":41},"Chinese University of Hong Kong",{"id":255,"slug":256,"hasResults":11,"nctId":257,"briefTitle":258,"officialTitle":258,"acronym":259,"eligibilityCriteria":260,"healthyVolunteers":11,"sex":16,"minAge":261,"maxAge":4,"enrollmentInfo":262,"targetDuration":4,"studyType":219,"phases":4,"briefSummary":264,"conditions":265,"keywords":267,"overallStatus":62,"whyStopped":4,"lastUpdateSubmitDate":282,"lastUpdatePostDateStruct":283,"startDateStruct":285,"completionDateStruct":287,"leadSponsor":289,"locationsCount":5},"100629933","study-of-the-epidemiological-clinical-diagnostic-and-therapeutic-characteristics-of-gastric-cancers-in-algeria-100629933","NCT07481110","Study of the Epidemiological, Clinical, Diagnostic, and Therapeutic Characteristics of Gastric Cancers in Algeria","ECLIPSE-CG","Inclusion Criteria:\n\n* Patients aged 19 years and older\n* Histologically confirmed diagnosis of gastric cancer\n* Patients followed in the participating oncology departments\n* Informed consent obtained\n\nNon Inclusion Criteria:\n\n* Histological types other than carcinoma (e.g., GIST, lymphoma, sarcoma, etc.).\n* Secondary gastric tumors\n* Participation in an interventional study","19 Years",{"count":263,"type":21},1000,"The goal of this observational study is to describe the demographic, epidemiological, clinical, and outcome characteristics of patients with gastric cancer.\n\nIt also aims to analyze the diagnostic approaches and management strategies used in the care of these patients in Algeria.",[88,266,27],"Gastric (Stomach) Cancer",[88,268,269,270,271,272,273,274,275,276,277,278,279,280,281],"Gastric cancer in Algerian patients","Observational study","Patient outcomes","Oncology","Retrospective data","Treatment strategies","Diagnostic approaches","Clinical characteristics","Epidemiological data","Demographic data","Cross-sectional study","Real-world data","Algeria","Algerian Study","2026-03-25",{"date":284,"type":34},"2026-03-27",{"date":286,"type":34},"2025-08-05",{"date":288,"type":21},"2026-08-05",{"name":290,"class":41},"Société Algérienne de Formation et Recherche en Oncologie",{"id":292,"slug":293,"hasResults":11,"nctId":294,"briefTitle":295,"officialTitle":296,"acronym":4,"eligibilityCriteria":297,"healthyVolunteers":11,"sex":16,"minAge":51,"maxAge":18,"enrollmentInfo":298,"targetDuration":4,"studyType":22,"phases":300,"briefSummary":302,"conditions":303,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":305,"lastUpdatePostDateStruct":306,"startDateStruct":308,"completionDateStruct":310,"leadSponsor":312,"locationsCount":4},"100631541","phase-4-a-clinical-study-of-iparomlimab-and-tuvonralimab-combined-with-sox-following-heterogeneous-radiotherapy-as-first-line-treatment-for-unresectable-locally-advanced-or-metastatic-her2-negative-gastric-or-gastroesophageal-junction-adenocarcinoma-100631541","NCT07502027","A Clinical Study of Iparomlimab and Tuvonralimab Combined With SOX Following Heterogeneous Radiotherapy as First-line Treatment for Unresectable Locally Advanced or Metastatic HER2-negative Gastric or Gastroesophageal Junction Adenocarcinoma","A Multicenter, Single-arm, Exploratory Clinical Study of Iparomlimab and Tuvonralimab Combined With SOX Following Heterogeneous Radiotherapy as First-line Treatment for Unresectable Locally Advanced or Metastatic HER2-negative Gastric or Gastroesophageal Junction Adenocarcinoma","Inclusion Criteria:\n\n* Age 18-75 years, male or female.\n* Histologically or cytologically confirmed diagnosis of gastric or gastroesophageal junction adenocarcinoma.\n* Patients with no prior systemic therapy for locally advanced or metastatic gastric or gastroesophageal junction adenocarcinoma. For patients who received neoadjuvant or adjuvant chemotherapy or chemoradiotherapy with curative intent, the interval from the last treatment to disease progression must be at least 6 months.\n* HER-2 negative (IHC 1+ or IHC 2+\u002FFISH-negative).\n* Presence of radiation-eligible tumor lesions.\n* No anticipated need for tumor resection during the study treatment period.\n* ECOG performance status 0-1.\n* At least one measurable lesion per RECIST v1.1. Lesions that have received prior radiotherapy cannot be selected as target lesions unless they are the only measurable lesions and show unequivocal progression on imaging, in which case they may be considered as target lesions.\n* Expected overall survival ≥ 3 months.\n* Adequate function of major organs.\n\nExclusion Criteria:\n\n* Presence of other histologic components confirmed by histopathology or cytology, such as squamous cell carcinoma, undifferentiated carcinoma, neuroendocrine carcinoma, etc.\n* Prior treatment with any tumor immunotherapy, including immune checkpoint inhibitors (e.g., anti-PD-1, anti-PD-L1, anti-CTLA-4 antibodies), immune checkpoint agonists (e.g., antibodies targeting ICOS, CD40, CD137, GITR, OX40), or immune cell therapy (e.g., CAR-T cells).\n* Palliative local therapy to non-target lesions within 2 weeks before the first dose; or systemic non-specific immunomodulatory therapy (e.g., interleukin, interferon, thymosin) within 2 weeks before the first dose.\n* Clinically significant pleural effusion, pericardial effusion, or ascites requiring frequent drainage (≥ 1 time per month).\n* Known active or untreated brain metastasis, meningeal metastasis, spinal cord compression, or leptomeningeal disease. Patients with measurable lesions outside the central nervous system may be eligible if: they are asymptomatic after treatment, radiologically stable for at least 4 weeks before study treatment (no new or enlarging brain metastases), and have discontinued systemic corticosteroids and anticonvulsants for at least 2 weeks.\n* Gastrointestinal perforation, gastrointestinal fistula, or intra-abdominal abscess within 6 months before the first dose.\n* Clinically significant bleeding or definite bleeding diathesis within 6 months before the first dose, such as gastrointestinal bleeding, hemorrhagic gastric ulcer, or vasculitis, excluding asymptomatic positive fecal occult blood.\n* Arterial or venous thromboembolism within 6 months before the first dose, including cerebrovascular accident (transient ischemic attack, cerebral hemorrhage, cerebral infarction), deep vein thrombosis, pulmonary embolism, etc. Superficial venous thrombosis is permitted.\n* Clinically active hemoptysis or active diverticulitis.\n* Major surgery other than for gastric cancer diagnosis within 28 days before the first dose, or anticipated major surgery during the study period.\n* Severe infection (CTCAE grade \\> 2) within 4 weeks before the first dose, such as severe pneumonia, bacteremia, infectious complications requiring hospitalization; active lung inflammation on baseline chest imaging; or signs\u002Fsymptoms of infection or oral\u002Fintravenous antibiotic therapy within 14 days before the first dose, excluding prophylactic antibiotics.\n* Any active or history of autoimmune disease, including but not limited to: interstitial lung disease, colitis, hepatitis, hypophysitis, vasculitis, nephritis, hyperthyroidism. Hypothyroidism may be allowed if controlled by hormone replacement. Patients with fully resolved psoriasis or childhood asthma\u002Fallergies requiring no intervention in adulthood may be included; those requiring medical intervention with bronchodilators are excluded.\n* History of immunodeficiency, including positive HIV test, other acquired or congenital immunodeficiency diseases, organ transplantation, or allogeneic bone marrow transplantation.\n* Uncontrolled cardiac conditions, including but not limited to:\n\n  1. NYHA class ≥ II heart failure;\n  2. unstable angina;\n  3. myocardial infarction within 1 year;\n  4. clinically significant supraventricular or ventricular arrhythmia uncontrolled or poorly controlled despite intervention;\n  5. QTc \\> 450 ms (male); QTc \\> 470 ms (female).\n* Active tuberculosis confirmed by medical history or CT scan, active tuberculosis within 1 year before screening, or history of active tuberculosis \\> 1 year without standard treatment.\n* Active hepatitis: HBsAg positive with HBV DNA ≥ 2000 IU\u002FmL; HCV antibody positive with HCV viral load above the upper limit of normal.\n* Diagnosis of another malignancy within 5 years before the first dose, except malignancies with low risk of metastasis or death (5-year survival \\> 90%), such as adequately treated basal cell carcinoma or squamous cell carcinoma of the skin, or carcinoma in situ of the cervix.\n* Administration of live attenuated vaccine within 4 weeks before the first dose. If enrolled, patients must not receive live vaccines during the study or within 120 days after the last dose of iparomlimab and tuvonralimab.\n* Known hypersensitivity or intolerance to any study drug(s) and\u002For their components.\n* Toxicity from prior anti-tumor therapy that has not resolved to NCI-CTCAE v5.0 grade 0 or 1, or to the level specified in the inclusion\u002Fexclusion criteria, except alopecia or pigmentation.\n* Pregnant or lactating female.\n* Participation in another clinical study, unless it is an observational, non-interventional study or the follow-up period of an interventional study.\n* Any other conditions judged by the investigator that may result in premature discontinuation from the study, including other severe diseases (including psychiatric disorders) requiring concurrent treatment, alcoholism, drug abuse, family or social factors that may affect patient safety or compliance.",{"count":299,"type":21},55,[301],"PHASE4","This study is a domestic, multicenter, single-arm clinical trial designed to evaluate the efficacy and safety of heterogeneous radiotherapy (high and low dose) sequenced with iparomlimab and tuvonralimab plus SOX as a first-line treatment for unresectable locally advanced or metastatic HER2-negative gastric or gastroesophageal junction adenocarcinoma.",[27,304,57],"Gastric Cancer (GC)","2026-03-24",{"date":307,"type":34},"2026-03-30",{"date":309,"type":21},"2026-06-01",{"date":311,"type":21},"2029-06-30",{"name":313,"class":41},"Huazhong University of Science and Technology",{"id":315,"slug":316,"hasResults":11,"nctId":317,"briefTitle":318,"officialTitle":318,"acronym":4,"eligibilityCriteria":319,"healthyVolunteers":320,"sex":16,"minAge":321,"maxAge":322,"enrollmentInfo":323,"targetDuration":4,"studyType":219,"phases":4,"briefSummary":325,"conditions":326,"keywords":327,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":329,"lastUpdatePostDateStruct":330,"startDateStruct":332,"completionDateStruct":334,"leadSponsor":336,"locationsCount":4},"100618475","the-application-of-extracellular-vesicle-detection-in-gastric-juice-based-on-metamaterial-sensing-in-the-diagnosis-of-gastric-cancer-and-related-diseases-100618475","NCT07332104","The Application of Extracellular Vesicle Detection in Gastric Juice Based on Metamaterial Sensing in the Diagnosis of Gastric Cancer and Related Diseases","Inclusion Criteria:\n\n* Patients underwent gastroscopy and treatment at the Endoscopy Center of Beijing Friendship Hospital, Capital Medical University, and received pathological biopsy.\n* Previous gastroscopy suggested the possibility of lesions.\n* No previous history of gastrointestinal cancer.\n\nExclusion Criteria:\n\n* Patients could not cooperate with the examination or had contraindications to endoscopy.\n* Previous history of gastrointestinal tumors, gastrointestinal surgery, physical and chemical injuries of the gastrointestinal tract.\n* Severe bile reflux.\n* Take simethicone and other defoaming agents before examination.\n* Patients with serious diseases of heart, lung, kidney, brain, blood and other important organs.",true,"40 Years","70 Years",{"count":324,"type":21},100,"After obtaining informed consent from the patients, all the medical history and treatment records of the patients who underwent gastroscopy since the onset of the disease, as well as gastric fluid samples, including laboratory and imaging data, were collected and recorded. The medical history and treatment records and gastric fluid samples were analyzed.",[304,27],[115,328],"Extracellular vesicles","2025-12-28",{"date":331,"type":34},"2026-01-12",{"date":333,"type":21},"2025-12-15",{"date":335,"type":21},"2026-12-15",{"name":337,"class":41},"Beijing Friendship Hospital",{"id":339,"slug":340,"hasResults":11,"nctId":341,"briefTitle":342,"officialTitle":343,"acronym":4,"eligibilityCriteria":344,"healthyVolunteers":11,"sex":16,"minAge":345,"maxAge":346,"enrollmentInfo":347,"targetDuration":4,"studyType":22,"phases":348,"briefSummary":349,"conditions":350,"keywords":355,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":359,"lastUpdatePostDateStruct":360,"startDateStruct":362,"completionDateStruct":364,"leadSponsor":366,"locationsCount":42},"100608461","peri-habilitation-for-patients-with-gastric-cancer-100608461","NCT07201857","Peri-habilitation for Patients With Gastric Cancer","Peri-habilitation to Enhance Treatment Outcomes and Postoperative Recovery in Patients With Gastric Cancer","Inclusion Criteria:\n\n* Patients aged 65 years or older who have been diagnosed with gastric cancer and are scheduled to undergo surgical treatment or chemotherapy.\n\nExclusion Criteria:\n\n* Patients with severe conditions who are unable to undergo the intervention prior to surgical treatment or chemotherapy.\n* Patients with physical (e.g., musculoskeletal) or mental disorders that make participation in or continuation of the program impossible.\n* Patients judged to be at risk of additional physical burden from the intervention.","65 Years","90 Years",{"count":20,"type":21},[83],"This study aims to evaluate the clinical applicability of a peri-habilitation program in patients with gastric cancer by applying nutritional intervention for approximately two weeks before surgery and a combined exercise and nutrition intervention for about three weeks after hospital discharge, and by analyzing its effects on the prevention of postoperative complications and recovery.",[27,351,352,353,354],"Gastric Cancer Patient","Gastric Cancer Patients Undergoing Gastrectomy","Gastric Cancer Patients Undergoing Minimally Invasive Gastrectomy","Gastric Cancer Patients Undergoing Laparoscopic Gastrectomy",[356,29,357,358],"peri-habilitation","postoperative recovery","exercise intervention","2025-09-23",{"date":361,"type":34},"2025-10-01",{"date":363,"type":21},"2025-10-15",{"date":365,"type":21},"2026-12-31",{"name":367,"class":41},"Korea University Anam Hospital",{"id":369,"slug":370,"hasResults":11,"nctId":371,"briefTitle":372,"officialTitle":372,"acronym":4,"eligibilityCriteria":373,"healthyVolunteers":320,"sex":16,"minAge":51,"maxAge":374,"enrollmentInfo":375,"targetDuration":4,"studyType":219,"phases":4,"briefSummary":377,"conditions":378,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":379,"lastUpdatePostDateStruct":380,"startDateStruct":382,"completionDateStruct":384,"leadSponsor":385,"locationsCount":4},"100600381","screening-and-validation-of-serum-protein-biomarkers-for-early-diagnosis-of-gastric-cancer-100600381","NCT07096752","Screening and Validation of Serum Protein Biomarkers for Early Diagnosis of Gastric Cancer","Inclusion Criteria\n\nGastric cancer patients enrolled in this study must meet all of the following criteria:\n\n1. Male or female, aged ≥18 and ≤95 years.\n2. Histopathologically confirmed gastric cancer, as defined by the 2024 edition of the Chinese Society of Clinical Oncology (CSCO) Guidelines for the Diagnosis and Treatment of Gastric Cancer.\n3. No prior anti-tumor treatment (including radiotherapy, chemotherapy, targeted therapy, or immunotherapy).\n4. Availability of complete clinicopathological data and follow-up information.\n\nPatients with precancerous gastric lesions must meet all of the following criteria:\n\n1. Male or female, aged ≥18 and ≤95 years.\n2. Histopathologically confirmed absence of gastric cancer.\n3. Diagnosis consistent with precancerous gastric lesions as defined by the American Society for Gastrointestinal Endoscopy (ASGE, 2015 edition).\n4. Availability of complete clinicopathological data and follow-up information.\n\nHealthy controls must meet all of the following criteria:\n\n1. Male or female, aged ≥18 and ≤95 years.\n2. Histopathologically confirmed absence of gastric cancer.\n3. No evidence of precancerous gastric lesions.\n4. Availability of complete clinicopathological data and follow-up information.\n\nExclusion Criteria\n\nPatients meeting any of the following conditions will be excluded:\n\n1. History of prior malignancy or cancer treatment.\n2. Presence of concurrent malignancies of other types.\n3. Inability to tolerate gastroscopy.","95 Years",{"count":376,"type":21},1200,"This study focuses on the discovery of protein biomarkers for the early diagnosis of gastric cancer and the development of corresponding detection methods. By employing advanced mass spectrometry-based proteomic technologies, the investigators conducted an in-depth analysis of a large cohort of clinical samples to identify specific protein biomarkers capable of accurately distinguishing gastric cancer patients from healthy individuals. The findings from this research are expected to facilitate the development of novel non-invasive or minimally invasive diagnostic approaches, thereby improving early detection, enhancing patient prognosis, and increasing survival rates.",[27],"2025-07-30",{"date":381,"type":34},"2025-07-31",{"date":383,"type":21},"2025-08-01",{"date":311,"type":21},{"name":386,"class":41},"Shanghai Zhongshan Hospital",{"id":388,"slug":389,"hasResults":11,"nctId":390,"briefTitle":391,"officialTitle":392,"acronym":4,"eligibilityCriteria":393,"healthyVolunteers":11,"sex":16,"minAge":51,"maxAge":394,"enrollmentInfo":395,"targetDuration":4,"studyType":219,"phases":4,"briefSummary":397,"conditions":398,"keywords":402,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":405,"lastUpdatePostDateStruct":406,"startDateStruct":408,"completionDateStruct":409,"leadSponsor":411,"locationsCount":413},"100599765","comparison-of-the-sensitivity-of-pcle-and-pathological-biopsy-before-esd-100599765","NCT07088744","Comparison of the Sensitivity of pCLE and Pathological Biopsy Before ESD","Comparison of the Sensitivity of Probe-based Confocal Laser Endomicroscopy and Pathological Biopsy Before Endoscopic Submucosal Dissection","Inclusion Criteria:\n\n* patients aged 18 to 85 years who were scheduled for endoscopic submucosal dissection due to early-stage gastric cancer were consecutively enrolled.\n\nExclusion Criteria:\n\n* Severe cardiac or pulmonary dysfunction, impaired renal function, coagulopathy, pregnancy or lactation, allergy to fluorescein, and inability to provide informed consent.","80 Years",{"count":396,"type":21},169,"Pathological biopsy before endoscopic submucosal dissection (ESD) the gastric lesion plays an important role in differentiating the pathological nature of the lesion and guiding treatment decisions. However, due to the influence of the materials used, the sensitivity of pathological biopsy is not satisfactory. Confocal Laser Endomicroscopy (CLE) is a technology that integrates a confocal microscope into an endoscope. It enables the acquisition of high-resolution microscopic images of the mucosal layer in real-time (with a magnification of up to 1000 times), and it is an optical biopsy technique. It has unique value in the determination of the pathological nature of gastric lesions. The main purpose of this study is to compare the sensitivity of pathological biopsy and CLE in differentiating the pathological nature of gastric lesions.",[27,399,400,401],"Gastric High-grade Intraepithelial Neoplasia","Gastric Low-grade Intraepithelial Neoplasia","Gastritis",[403,404],"Confocal Laser Endomicroscopy","pathological biopsy","2025-07-19",{"date":407,"type":34},"2025-07-28",{"date":379,"type":21},{"date":410,"type":21},"2025-09-15",{"name":412,"class":41},"Changhai Hospital",4]